GSK files albiglutide at FDA for treatment of Type 2 Diabetes
GlaxoSmithKline (GSK) plc has announced a regulatory submission to the FDA for albiglutide, an investigational once-weekly treatment for adult patients with Type 2 Diabetes. Albiglutide is not yet approved as a treatment for Type 2 Diabetes or any other indication anywhere in the world.
Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of Type 2 Diabetes designed for once-weekly subcutaneous dosing.
GSK intends to submit a regulatory application in the European Union (EU) in early 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.